New hope for kids with severe arthritis: drug shows promise in reducing symptoms and steroid use
NCT ID NCT00339157
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tested a drug called anakinra in 24 children and young adults (ages 2-20) with severe systemic juvenile idiopathic arthritis that did not respond well to steroids. For the first month, half received anakinra and half received a placebo, then all received anakinra for 11 more months while slowly reducing steroids. The goal was to see if anakinra could improve arthritis symptoms and help patients use less steroids over a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bordeaux CHU
Bordeaux, 33000, France
-
Hopital Lyon Edouard Herriot
Lyon, 69437, France
-
Kremlin-Bicetre Hospital
Paris, 94270, France
-
Nancy Hopital d'Enfants
Nancy, 54511, France
-
Pediatric Immuno-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, 149 rue de Sevres
Paris, 75015, France
-
Robert Debre Hospital
Paris, 75019, France